The FDA finalized clinical guidance for psychedelic drug developers and scheduled a public hearing on future therapeutic use, adding regulatory momentum to the psychedelic pipeline. The agency’s move is intended to clarify development expectations for sponsors seeking to study and potentially market psychedelic therapies. For biotech and pharma, the filing and hearing function as a near-term catalyst for clinical planning—helping companies align trial designs, endpoints, and regulatory strategy with agency priorities. It also signals continued traction for psychedelic medicines as a therapeutic category. In parallel, the FDA has been advancing other regulatory modernization efforts, which collectively are changing the operating environment for clinical development timelines and evidence packages across therapeutic areas.